Loading
BR
Bio-Rad Laboratories, Inc. Stock: price and insider trades · United States
Bio-Rad Laboratories, Inc.: what insiders have been doing
Bio-Rad Laboratories, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 18 October 2026, brought 56 filings signed by 13 insiders.
No insider bought on the market over the period, while 2 insiders filed 2 sales totalling €301k. Biggest ticket of the year: €186k, sold by Barry James and made public on 10 November 2025.
With 56 filings in twelve months, the company is more active than the median of 19 filings across the 5,811 companies we follow on the same exchange. Our records for Bio-Rad Laboratories, Inc. go back to 2021, with no purchases and 15 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 2.58 bn USD and net income of 759.9 m USD.
Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
192
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€3M
15 ops. · all time
Who traded when
BuySaleEva Anette Engelhardt1 sale
James Barry1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
Income statement
RevenueUS$2.2B
Gross profitUS$1.2B52% margin
Net incomeUS$654.3M29.4% margin
Last declaration on 9 September 2026
Declarations192 total
228 shares0Bio-Rad A Common StockSEC:0001924980-26-000004:0
92 shares0Bio-Rad A Common StockSEC:0001924980-26-000004:2
1,027 shares0Bio-Rad A Common StockSEC:0002022345-26-000004:0
1,056 shares0Bio-Rad A Common StockSEC:0002022345-26-000004:2
4,109 shares0Bio-Rad A Common StockSEC:0000940805-26-000004:0
3,455 shares0Bio-Rad A Common StockSEC:0000940805-26-000004:2
1,536 shares0Bio-Rad A Common StockSEC:0001396867-26-000004:2
1,027 shares0Bio-Rad A Common StockSEC:0001993147-26-000002:0
864 shares0Bio-Rad A Common StockSEC:0001993147-26-000002:2
685 shares0Bio-Rad A Common StockSEC:0002019843-26-000004:0
1,027 shares0Bio-Rad A Common StockSEC:0002024911-26-000006:0
1,152 shares0Bio-Rad A Common StockSEC:0002024911-26-000006:2
456 shares0Bio-Rad A Common StockSEC:0002081681-26-000002:0
1,370 shares0Bio-Rad A Common StockSEC:0002081681-26-000002:2
369 shares@ US$386.1121.9% of flowBio-Rad A Common StockSEC:0002022345-26-000004:1
277 shares@ US$386.1119.6% of flowBio-Rad A Common StockSEC:0001993147-26-000002:3
233 shares@ US$386.1131.6% of flowBio-Rad A Common StockSEC:0002081681-26-000002:1
82 shares@ US$386.1151.6% of flowBio-Rad A Common StockSEC:0001924980-26-000004:1
34 shares@ US$386.1121.4% of flowBio-Rad A Common StockSEC:0001924980-26-000004:3
470 shares@ US$386.1127.9% of flowBio-Rad A Common StockSEC:0002022345-26-000004:3
2,876 shares@ US$386.119.4% of flowBio-Rad A Common StockSEC:0000940805-26-000004:1
1,854 shares@ US$386.116.1% of flowBio-Rad A Common StockSEC:0000940805-26-000004:3
1,370 shares0Bio-Rad A Common StockSEC:0001396867-26-000004:0
559 shares@ US$386.1127.0% of flowBio-Rad A Common StockSEC:0001396867-26-000004:1
782 shares@ US$386.1137.8% of flowBio-Rad A Common StockSEC:0001396867-26-000004:3
25 of 192 declarations
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. is a U.S.-based life sciences and clinical diagnostics company listed on the NYSE/NASDAQ under the tickers BIO and BIO.B. Headquartered in Hercules, California, in the United States, the company was founded in 1952 in Berkeley by David and Alice Schwartz. Over time, Bio-Rad has built a reputation as a specialized provider of laboratory tools, diagnostics, and quality-control solutions, serving both research and clinical end markets.
The business is organized into two core segments. Life Science supplies instruments, software, consumables, and reagents used to separate, purify, characterize, and quantify biological materials such as cells, proteins, and nucleic acids. These products are sold to universities, research institutes, pharmaceutical and biotechnology companies, and industrial laboratories, with additional use cases in biomanufacturing, process quality control, food safety, and science education. Clinical Diagnostics provides in vitro diagnostic products, including quality-control systems, blood typing and transfusion products, electrophoresis platforms, and solutions used in hospital and reference laboratories. The segment also has exposure to diabetes monitoring and other routine diagnostic workflows.
Read moreShow less
Bio-Rad has a global operating footprint across research, manufacturing, and sales, giving it broad geographic reach and access to customers in North America, Europe, Asia, and other international markets. Its competitive position is shaped by technical specialization, a recurring consumables base, and long-standing relationships with laboratory and clinical customers. In many of its end markets, it competes with larger diversified healthcare and life science players such as Thermo Fisher, Danaher, Roche, Abbott, and other niche diagnostic specialists, depending on the product category. Bio-Rad’s differentiation lies in its depth in analytical tools, immunohematology, quality control, and advanced molecular workflows.
Recent company updates in 2025 have highlighted mixed end-market conditions. Management has pointed to a tougher academic and biotech funding environment affecting Life Science, while Clinical Diagnostics has shown a more normalized growth profile. Bio-Rad has also emphasized strategic moves in digital PCR, including acquisition-led expansion and platform rollout, as well as partnerships aimed at oncology-related in vitro diagnostic applications. For investors, Bio-Rad stands out as a specialized, innovation-driven healthcare tools company with exposure to scientific research spending, diagnostic testing demand, and high-value recurring laboratory workflows in the United States and abroad.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
